UK Regulator Clears Wegovy Tablet; Novo Nordisk Shares Tick Higher
Novo Nordisk shares rose after the UK’s Medicines and Healthcare products Regulatory Agency approved a daily semaglutide tablet - the first GLP-1 receptor agonist tablet authorized for weight loss in the UK. The tablet is approved for adults with obesity or overweight adults with at least one weight-related comorbidity; strict dosing, administratio…